A long history of β-lactams for MRSA

Article metrics

Since the emergence of methicillin-resistant Staphylococcus aureus 60 years ago, scientists have been trying to engineer β-lactam antibiotics to restore drug susceptibility. Genomic data now shows that clavulanic acid (a β-lactamase inhibitor) can restore susceptibility in many strains, but only if they carry key mutations.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Evolution of penicillin–clavulanic acid susceptibility.


  1. 1.

    Kourtis, A. P. et al. MMWR-Morbid. Mortal. W. 68, 214–219 (2019).

  2. 2.

    Harrison, E. M. et al. Nat. Microbiol. (2019).

  3. 3.

    Cantoni, L., Wenger, A., Glauser, M. P. & Bille, J. J. Infect. Dis. 159, 989–993 (1989).

  4. 4.

    Nicolas, M. H., Kitzis, M. D. & Karim, A. Med. Maladies Infect. 23, 82–94 (1993).

  5. 5.

    Andreoni, M., Raillard, P., Concia, E. & Wang, Y. Curr. Ther. Res. Clin. E. 50, 386–395 (1991).

  6. 6.

    Chambers, H. F., Sachdeva, M. & Kennedy, S. J. Infect. Dis. 162, 705–710 (1990).

  7. 7.

    Chambers, H. F., Kartalija, M. & Sande, M. J. Infect. Dis. 171, 897–902 (1995).

Download references

Author information

Correspondence to Fergus Hamilton.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark